← Back to Clinical Trials
Recruiting NCT06748248

NCT06748248 Suspension Therapy Effects on Mobility and Balance in Down Syndrome

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT06748248
Status Recruiting
Phase
Sponsor Riphah International University
Condition Down Syndrome (DS)
Study Type INTERVENTIONAL
Enrollment 26 participants
Start Date 2024-09-24
Primary Completion 2025-01-10

Eligibility & Interventions

Sex All sexes
Min Age 3 Years
Max Age 6 Years
Study Type INTERVENTIONAL
Interventions
suspension TherapyRoutine Treatment

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.

This trial targets 26 participants in total. It began in 2024-09-24 with a primary completion date of 2025-01-10.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

Down syndrome (DS) is one of the most common congenital disorders. Individuals with Down syndrome present with several impairments such as hypotonia, ligament laxity, decreased muscle strength, insufficient muscular co-contraction, inadequate postural control, and disturbed proprioception. These factors are responsible for the developmental challenges faced by children with Down syndrome. These individuals also present with balance dysfunctions. Neuromuscular and musculoskeletal impairments due to the chromosomal abnormality lead to developmental delay. These children also exhibit poor balance with greater instability and inefficient compensatory mechanisms including altered center of pressure displacement and trunk stiffening that predisposes them to falls. The aim of this study is to determine the Effects of Suspension Therapy (ST) on mobility and balance of children with Down syndrome. Suspension Therapy using Universal exercise Unit (UEU) is a three dimensional (3D) cage, consists of system of pulleys, suspensions, belts for supporting and elastic cords. Suspension Therapy is based on the concept of unloading the body against gravity and to perform movement of weak part of body.

Eligibility Criteria

Inclusion Criteria: • Diagnosed children with Down syndrome with mild (IQ: 69-50) to moderate (IQ: 50-35) mental retardation * Aged between 3 to 6 years * Both gender * Able to follow the instructions * Able to stand and walk Exclusion Criteria: • Any Cardiovascular disease * Visual and Hearing impairment * Orthopedic limitation to exercise such as hip, knee, foot or spinal deformities

Contact & Investigator

Central Contact

Imran Amjad Dr, PhD

✉ Imran.amjad@riphah.edu.pk

📞 9233224390125

Principal Investigator

Sidra Rukhsar, MS

PRINCIPAL INVESTIGATOR

Riphah International University

Frequently Asked Questions

Who can join the NCT06748248 clinical trial?

This trial is open to participants of all sexes, aged 3 Years or older, up to 6 Years, studying Down Syndrome (DS). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT06748248 currently recruiting?

Yes, NCT06748248 is actively recruiting participants. Contact the research team at Imran.amjad@riphah.edu.pk for enrollment information.

Where is the NCT06748248 trial being conducted?

This trial is being conducted at Lahore, Pakistan, Lahore, Pakistan.

Who is sponsoring the NCT06748248 clinical trial?

NCT06748248 is sponsored by Riphah International University. The principal investigator is Sidra Rukhsar, MS at Riphah International University. The trial plans to enroll 26 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology